[ACX 2026] Will the US, UK or EU approve a gene editing therapy for a new condition during 2026?
EuropaOne-OffGesundheit & MedizinWissenschaft2MonManifold MarketsKein KYCVerifizierte AuflösungsdatenOrdentlich kalibriertWarnung zur DatenqualitätQuelldaten beeinträchtigt
Daten vom 24.10.2026, 01:51 UTC · Richtlinie pm-quality-4
Aktuelle Community-PrognoseNein 90.2%
Prognostiker
29
Fragetyp
binary
Methodik
Play-money forecasting platform
Quellentyp
Prognose
Marktdaten
Aktualisiert vor 11 Stunden
Veraltet6. Jan. 26, 22:51 UTC31. Dez. 26, 23:59 UTC
Trends
Verwandte Märkte
Verwandte Fragen als Kontext, kein Vergleich gleichwertiger Kontrakte.
When will commercial gene-editing therapy be available?
Manifold MarketsWill a CRISPR-based gene editing therapy for transthyretin (ATTR) amyloidosis be available in the US by 2027?
Manifold MarketsBy 2030, will gene editing to cure serious genetic diseases be seen as generally uncontroversial?
Manifold MarketsWill GiveWell research gene-editing mosquitoes to eradicate malaria?
Manifold MarketsThere will be more children born via artificial wombs than not in first world countries before 2050
Manifold MarketsPreimplantation genetic diagnosis liberalised in Germany before 2027?
Manifold MarketsRegeln
(https://www.metaculus.com/questions/embed/41169) Resolves according to Metaculus resolution.
- Metaculus high-level description: This question will resolve as Yes if any of the US FDA, UK MHRA, or the EU Commission authorizes the use or sale of a therapy whose primary mechanism directly editing the patient's genomic DNA for any human condition other than sickle cell disease and beta thalassemia before January 1, 2027.
